Primary tabs

Siva Kolluri

Professor
siva.kolluri [at] oregonstate.edu

Office: 541-737-1799

Read more about Dr. Kolluri and his lab at: https://emt.oregonstate.edu/users/siva-kolluri?gid=16025.  
Research Focus:

Our laboratory has expertise in the investigation of biological activity of chemical compounds and their mechanisms of action. Research in the Kolluri laboratory includes investigation of the pathways regulating cell cycle, cell death and differentiation.

Currently, the Kolluri laboratory is investigating Aryl hydrocarbon Receptor (AhR)-mediated pathways that regulate anti-cancer functions. We have discovered and developed a new class of compounds termed as Select Modulators of AhR-regulated Transcription” (SMAhRTs). SMAhRTs are effective against certain cancers including human hepatocellular carcinoma, a common type of liver cancer, and against triple negative breast cancers, which account for about 15% of breast cancers with the worst prognosis. The Kolluri laboratory is elucidating the molecular mechanisms of SMAhRT-induced anti-cancer effects mediated by AhR signaling.

The Kolluri laboratory is also investigating mechanisms of therapeutic resistance in cancers. Human cancers express Bcl -2, a protein that gives survival advantage to cancer cells. Increased expression of this protein allows the cancer cells to resist chemotherapy treatments and survive. We have an invention to change Bcl-2 from a cancer protective to a cancer destructive protein and have developed ‘first-in-class’ small molecules that change Bcl-2 into a cancer cell killer. The Kolluri laboratory is investigating the therapeutic utility of this innovation in cancers.

Recent publications from our laboratory:

Jessica L. Phillips, Christiane Loehr, Bach D. Nguyen, Andrew B. Buermeyer, Siva K. Kolluri. Loss of the aryl hydrocarbon receptor increases tumorigenesis in p53-deficient mice. Toxicology and Applied Pharmacology, August 2022 (in press).

Bach D. Nguyen, Brenna L. Stevens, Daniel J. Elson, Darren Finlay, John Gamble, Prasad Kopparapu, Robyn L. Tanguay, Andrew B. Buermeyer, Nancy I. Kerkvliet, Siva K. Kolluri. A Select Modulator of AhR-regulated Transcription Suppresses Cancer Cell Growth. The FEBS Journal, September 2022 (Accepted).

Elson DJ, Nguyen BD, Wood R, Zhang Y, Puig-Sanvicens V, Kolluri SK. The cyclin-dependent kinase inhibitor p27Kip1 interacts with the aryl hydrocarbon receptor and negatively regulates its transcriptional activity. FEBS Lett. 2022. doi: 10.1002/1873-3468.14434

Vermillion Maier ML, Siddens LK, Uesugi SL, Choi J, Leonard SW, Pennington JM, Tilton SC, Smith JN, Ho E, Chow HHS, Nguyen BD, Kolluri SK, Williams DE. 3,3'-Diindolylmethane Exhibits Significant Metabolism after Oral Dosing in Humans. Drug Metab Dispos. 2021. 49(8):694-705. doi: 10.1124/dmd.120.000346

Discovery and Mechanistic Characterization of a Select Modulator of AhR-regulated Transcription (SMAhRT) with Anti-cancer Effects. Apoptosis. 2021. doi: 10.1007/s10495-021-01666-0

https://factor.niehs.nih.gov/2021/6/papers/cancer-fighting-compounds/index.htm

https://link.springer.com/article/10.1007/s10495-021-01666-0

https://link.springer.com/article/10.1007/s10495-021-01672-2

Conversion of Bcl-2 from a protector to a killer in cancer cells: Bcl-2-family proteins are evolutionarily conserved regulators of cell death. The Bcl-2 family primarily acts on mitochondria to regulate cell death. Overexpression of Bcl-2 contributes to cancer development and tumor progression by blocking pro-cell death Bcl-2 family members. The overexpression of Bcl-2 correlates with poor survival and correlates with resistance of cancer cells to many chemotherapeutic drugs and radiation. 

We discovered a novel pathway in which Bcl-2 is converted from a protector to a killer protein (Cell 116, 527-540, 2004; Cancer Cell, 14:285-98, 2008; Oncotarget, 9:26072-26085, 2018; Apoptosis, 24:1-2 & 24:529-537, 2019). The dramatic change in Bcl-2 function is brought about by orphan nuclear receptor Nur77 binding, which exposes a hidden ‘killer BH3 domain’ of Bcl-2. We reported the identification of a Nur77-derived Bcl-2-converting peptide with 9 amino acids (NuBCP-9) and its enantiomer, which induce apoptosis of cancer cells in vitro and in animals. The apoptotic effect of NuBCPs are not inhibited but rather potentiated by Bcl-2 expression. NuBCP-9 and its enantiomer bound to the Bcl-2 loop, which shares the characteristics of structurally adaptable regions with many cancer-associated and signaling proteins. This discovery enabled extremely exciting new research possibilities, providing a molecular basis for the design and development of novel cancer therapeutics.

Cancer protector into killer: https://extension.oregonstate.edu/news/osu-helps-turn-cancer-protector-killer

Cancer therapeutics based on BCL-2 functional conversion. https://link.springer.com/article/10.1007%2Fs10495-018-1504-5

The major goal of our laboratory is to identify small molecules that convert Bcl-2 from a protector to a killer protein, establish their therapeutic efficacy in various cancer models and move these ‘first-in-class’ cancer therapeutics to the clinic and help cancer patients.

Ah Receptor as a therapeutic target in cancer: Ah receptor (AhR) is a ligand activated transcription factor belonging to the basic-helix-loop-helix (bHLH)-Per-Arnt-Sim (PAS) protein family. The bHLH/PAS family proteins are heterodimeric transcription factors that sense and respond to external or physiological signals such as hypoxia and circadian rhythms.

AhR has been implicated as a tumor suppressor and continues to gain interest as a potential therapeutic target in cancer. We have reported that high AhR expression is associated with increased relapse-free survival and distant metastasis free survival in patients with hormone independent breast cancer.  The major focus of our laboratory is to (i) investigate AhR signaling in tumor suppression and (ii) characterize the mechanism of action of Select Modulators of AhR-regulated Transcription with anti-cancer effects (Apoptosis, 2021. https://doi.org/10.1007/s10495-021-01666-0; https://doi.org/10.1007/s10495-021-01672-2).

We have developed AhR ligand binding pocket models to understand AhR ligand binding pocket interactions with distinct classes of chemical compounds. We have generated new mouse models to understand AhR mediated tumor suppression in the context of p53 tumor suppressor gene deletion (in collaboration with Dr. Christiane Loehr at OSU).

We are also investigating AhR mediated signaling in the immune system (in collaboration with Dr. Nancy Kerkvliet; PLoS One, 9:e88726, 2014; Journal of immunology, 196: 264-732016, 2016; Eur J Immunol., 47:1989-2001, 2017), in zebrafish (in collaboration with Dr. Robyn Tanguay) and we are examining the required properties of select AhR modulators that activate the anti-cancer actions of the AhR (Cell Death Dis., 5:e1038, 2014; Oncogene, 34:6092-104, 2015; Oncotarget, 8:25211-25225, 2017; Arch Toxicol. 91:2497-2513, 2017; Biology, 6: 2017; Apoptosis, 2021. https://doi.org/10.1007/s10495-021-01666-0; https://doi.org/10.1007/s10495-021-01672-2).

Osteoporosis drug for treatment of breast and liver cancers:  https://www.niehs.nih.gov/news/newsletter/2014/4/science-osteoporosisdrug/

New chemical to prevent Type 1 diabetes:  http://oregonstate.edu/ua/ncs/archives/2016/jan/new-chemical-could-yield-therapy-prevent-type-1-diabetes

We have discovered highly AhR selective ligands for treatment of certain breast cancers, Type 1 diabetes and are in the process of optimizing therapeutic leads for clinical translation.
Apoptosis, 2021. https://doi.org/10.1007/s10495-021-01666-0

https://rdcu.be/cjlcU

https://link.springer.com/article/10.1007/s10495-021-01672-2  

Hypoxia-inducible Factor as a Target for Cancer Therapy: A major strategy in developing new cancer chemotherapeutics is to identify and target biological processes that differ between normal and malignant cells. Hypoxia, a reduction in the normal level of oxygen in tissue, occurs during cancer progression. Tumors become hypoxic because their new blood vessels are abnormal and they outgrow their blood supply. Cancer cells undergo genetic and adaptive changes that allow them to survive and proliferate in a hypoxic environment. These processes contribute to malignancy and aggressive tumor behavior.

Hypoxia inducible factor 1 (Hif-1) is a key protein factor induced by hypoxia and is involved in determining the levels of many protein factors in cancer cells. Vascular endothelial growth factor (VEGF), which promotes new blood vessel growth in tumors, is one of the important genes induced by Hif-1. Other genes regulated by Hif-1 activation are expressed at higher levels in cancer cells than in their normal tissue counterparts, and have roles in progression cancer. Hif-1 activity is also correlated with poor response to radiation therapy and chemotherapy. Our laboratory is interested in identifying pathways that disrupt Hif-1signaling in cancer cells in order to develop novel cancer therapeutics.

Sci Rep. 10(1):727 (2020)

https://pubmed.ncbi.nlm.nih.gov/31959767/

---------------

Postdoctoral Positions

NIH-NIEHS postdoctoral training grant positions are available at Oregon State University (OSU).

Candidates who will be graduating soon or who have received PhD in the last five years and have interests in broad areas of toxicology, molecular biology, or cell signaling, please contact Siva Kolluri (Siva.kolluri@oregonstate.edu; @ phone no. 541-737-1799). 

The appointees will have an opportunity of collaborating with multiple PIs across the OSU campus, Pacific Northwest National Laboratory (PNNL) and Oregon Health & Science University (OHSU) and also pursue their own research interests.

Education: 

Post Doctoral Research
Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.
Mentor: Professor Xiao-kun Zhang

Ph.D. - Magna Cum Laude
The Institute of Genetics, Forschungszentrum Karlsruhe, Germany
(Director: Professor Peter Herrlich)
Thesis Mentor: Professor Martin Göttlicher

Master of Technology (Bio-Technolgy)
Jadavpur University, Calcutta, India

Bachelor of Pharmacy (Hons.)
Biria Institute of Technology and Science, Pilani, India

 

Honors: 

National Merit Scholar

University Gold Medal, Jadavpur University, Calcutta, India

Department of Defense Breast Cancer Research Program Post-doctoral Scholar

New Investigator Award of the California Tobacco Related Disease Research Program

American Cancer Society Research Scholar

 

Professional Affiliations:

Cancer Prevention and Intervention Program, Linus Pauling Institute, Oregon State University

Department of Biomedical Sciences, Oregon State University

Department of Biochemistry & Biophysics, Oregon State University

 

Patents

Siva Kumar Kolluri, Nancy I. Kerkvliet et al., Aryl Hydrocarbon Receptor Activators. 2022.

Kolluri, S.K., Kopparapu, P; Pearce, M. Bcl-2 functional converters. 2022.

Nancy I. Kerkvliet and Siva Kumar Kolluri. Compounds and Methods to suppress autoimmune response. Patent No. # US10308649B2, 2019;

Nancy I. Kerkvliet and Siva Kumar Kolluri. Compounds and Methods to suppress autoimmune response. European patent application: EP15855322.2

Nancy I. Kerkvliet and Siva Kumar Kolluri. Compounds and Methods to suppress autoimmune response. Application No. PCT/US15/57873; 15855322.2 (European application 2017); 15/522,241 (U.S. application 2017)

Satterthwait, A., Zhang, X.K, Zhu, X., and Kolluri, S.K. Methods of regulating apoptosis. Patent No. # US20100292145A1, 2010.

Kolluri, S.K., Zhu, X., Zhang, X., and Satterthwait, A. Targeting Bcl-2 family proteins with cell-permeable peptides. US Patent No. # 20070054863, 2008.

Reed, J.C., Zhang, X., Gao, B., Lin, B. and Kolluri, S.K. Bcl-2 Converters for Cancer. US Patent No. # 6,994,979, 2006.

Göttlicher, M., Kolluri, S.K., and Weiss, C. Method for producing agents for treating tumor diseases and for immunosuppression Patent No. # US 6,482,610 B1, 2002.

Göttlicher, M., Kolluri, S.K., and Weiss, C. Method for evaluation of toxicity of environmental pollutants. Patent No. # Europe 198 11 326, 1999.

 

Research Team

1. Daniel Elson: PhD candidate

2. Nick Korjeff: MS student

3. Yi Zhang: MS student

4. Kyla Guertin: Research Assistant

5. Rhand Wood: Undergraduate Honors thesis student

Select Publications: Citations >5500, h-index: 33

https://scholar.google.com/citations?user=sZFSc3cAAAAJ&hl=en

O'Donnell EF 3rd, Jang HS, Liefwalker DF, Kerkvliet NI, Kolluri SK. Discovery and Mechanistic Characterization of a Select Modulator of AhR-regulated Transcription (SMAhRT) with Anti-cancer Effects. Apoptosis. 2021 Apr 24. doi: 10.1007/s10495-021-01666-0. PMID: 33893898.

https://rdcu.be/cjlcU

Gamble JT, Elson DJ, Greenwood JA, Tanguay RL, Kolluri SK. The Zebrafish Xenograft Models for Investigating Cancer and Cancer Therapeutics. Biology (Basel). 2021, 10(4):252. doi: 10.3390/biology10040252. PMID: 33804830.

Song Z, Pearce MC, Jiang Y, Yang L, Goodall C, Miranda CL, Milovancev M, Bracha S, Kolluri SK, Maier CS. Delineation of hypoxia-induced proteome shifts in osteosarcoma cells with different metastatic propensities. Scientific Reports. 10:727, 2020. PMID: 31959767.

https://www.nature.com/articles/s41598-019-56878-x

Larkey NE, Phillips JL, Jang HS, Kolluri SK, Burrows SM. Small RNA Biosensor Design Strategy To Mitigate Off-Analyte Response. ACS Sens. 5:377-384, 2020. PMID: 31942801.

https://pubs.acs.org/doi/10.1021/acssensors.9b01968

Morgan E, Gamble JT, Pearce MC, Elson DJ, Tanguay RL, Kolluri SK, Reich NO. Improved in vivo targeting of BCL-2 phenotypic conversion through hollow gold nanoshell delivery. Apoptosis. 24:529-537, 2019. PMID: 30879165.   https://link.springer.com/article/10.1007%2Fs10495-019-01531-1

Pearce MC, Satterthwait AC, Zhang XK, Kolluri SK. Cancer therapeutics based on BCL-2 functional conversion. Apoptosis. 24:1-2, 2019. PMID: 30612317. https://link.springer.com/article/10.1007%2Fs10495-018-1504-5

Pearce, M.C., Gamble, J.T., Kopparapu, P.R., O’Donnell, E.F., Mueller, M.J., Jang, H.S., Greenwood, J.A., Satterthwait, A.C., Tanguay, R.L., Zhang, X.-K. and Kolluri, S.K. Induction of apoptosis and suppression of tumor growth by Nur77-derived Bcl-2 converting peptide in chemoresistant lung cancer cells. Oncotarget. 9: 26072–26085, 2018. PMID: 29899843

Kolluri, S.K, Jin UH, Safe S. Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target. Arch Toxicol. 91(7):2497-2513, 2017. PMID: 28508231.

Jang, H.S.; Pearce, M.; O’Donnell, E.F.; Nguyen, B.D.; Truong, L.; Mueller, M.J.; Bisson, W.H.; Kerkvliet, N.I.; Tanguay, R.L.; Kolluri, S.K. Identification of a Raloxifene Analog That Promotes AhR-Mediated Apoptosis in Cancer Cells. Biology, 6, 41: 2017. PubMed PMID: 29194351.

Ehrlich AK, Pennington JM, Tilton S, Wang X, Marshall NB, Rohlman D, Funatake C, Punj S, O'Donnell E, Yu Z, Kolluri S.K, Kerkvliet NI. AhR activation increases  IL-2 production by alloreactive CD4(+) T cells initiating the differentiation of  mucosal-homing Tim3(+) Lag3(+) Tr1 cells. Eur J Immunol. 47:1989-2001, 2017. PMID: 28833046.

Allison K. Ehrlich, Jamie M. Pennington, Xisheng Wang, Diana Rohlman, Sumit Punj, Christiane Loehr, Matthew T. Newman, Siva K. Kolluri, and Nancy I. Kerkvliet; Activation of the Aryl Hydrocarbon Receptor Prevents Insulitis and Effector T Cell Development Independently of Foxp3+ Regulatory T Cells in Non-obese Diabetic Mice. Journal of immunology 196: 264-732016, 2016. PMID: 26573835.

New chemical to prevent Type 1 diabetes. http://oregonstate.edu/ua/ncs/archives/2016/jan/new-chemical-could-yield-therapy-prevent-type-1-diabetes

O'Donnell EF, Jang HS, Pearce M, Kerkvliet NI, Kolluri, S.K. The aryl hydrocarbon receptor is required for induction of p21cip1/waf1 expression and growth inhibition by SU5416 in hepatoma cells. Oncotarget. 8(15):25211-25225, 2017. PMID: 28424418.

Koch DC, Jang HS, O'Donnell EF, Punj S, Kopparapu PR, Bisson WH, Kerkvliet NI, Kolluri SK. Anti-androgen flutamide suppresses hepatocellular carcinoma cell proliferation via the aryl hydrocarbon receptor mediated induction of transforming growth factor-β1. Oncogene. 34:6092-104, 2015. PMID: 25867062

O'Donnell EF, Koch DC, Bisson WH, Jang HS, Kolluri SK. The aryl hydrocarbon receptor mediates raloxifene-induced apoptosis in estrogen receptor-negative hepatoma and breast cancer cells. Cell Death and Disease. 2014;5:e1038. doi: 10.1038/cddis.2013.549. PMID: 24481452   

Osteoporosis drug for treatment of breast and liver cancers.   https://www.niehs.nih.gov/news/newsletter/2014/4/science-osteoporosisdrug/

Punj S, Kopparapu P, Jang HS, Phillips JL, Pennington J, Rohlman D, O'Donnell  E, Iversen PL, Kolluri SK, Kerkvliet NI. Benzimidazoisoquinolines: A New Class of Rapidly Metabolized Aryl Hydrocarbon Receptor (AhR) Ligands that Induce AhR-Dependent Tregs and Prevent Murine Graft-Versus-Host Disease. PLoS One. 2014;9(2):e88726. PMID: 24586378

Researchers discover novel compound for treat autoimmune diseases.  https://www.niehs.nih.gov/news/newsletter/2014/5/science-autoimmune/index.htm

O'Donnell EF, Kopparapu PR, Koch DC, Jang HS, Phillips JL, Tanguay RL, Kerkvliet NI, Kolluri SK. The aryl hydrocarbon receptor mediates Leflunomide-induced growth inhibition of melanoma cells.  PLoS ONE. 7(7): e40926, 2012.

Murray IA, Flaveny CA, Chiaro CR, Sharma AK, Tanos RS, Schroeder JC, Amin SG,  Bisson WH, Kolluri SK, Perdew GH. Suppression of cytokine-mediated complement factor gene expression through selective activation of the Ah receptor with 3', 4'-dimethoxy-{alpha}-naphthoflavone. Molecular Pharmacology. 79:508-19, 2011.

Zhou H, Liu W, Su Y, Wei Z, Liu J, Kolluri SK et al. NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling. Cancer Cell. 17:560-73, 2010.

Bisson, W., Koch, D., O’Donnell, E., Khalil, S., Kerkvliet, N., Tanguay, R., Abagyan, R., and Kolluri, S.K. Modeling of the Aryl Hydrocarbon Receptor(AhR) ligand binding domain and its utility in virtual ligand screening to predict new AhR ligands. Journal of Medicinal Chemistry 52:5635-41, 2009.

Kolluri SK, Zhu X, Zhou X, Lin B, Chen Y, Sun K, Tian X, Town J, Cao X, Lin F, Zhai D, Kitada S, Luciano F, O'Donnell E, Cao Y, He F, Lin J, Reed JC, Satterthwait AC, Zhang XK. A short Nur77-derived peptide converts Bcl-2 from a protector to a killer. Cancer Cell. 2008 Oct 7;14(4):285-98.

News and views of the above Cancer Cell article

Bing Qi & J Marie Hardwick Bcl-2 turns deadly. Nature Chemical Biology, 4: 722-23, 2008.

Martz, L. BCL-2 double take; Nature Science-Business exchange; 1(39); doi:10.1038 scibx.2008.938.

Flemming, A. New strategies to tip the BCL-2 balance. Nature Reviews Drug Discovery, 7:977, 2008.

Aschheim, K., DeFrancesco, L., and Hare, P. Flipping for apoptosis. Nature Biotechnology 26:1250, 2008.

Kolluri SK, Corr M, James SY, Bernasconi M, Lu D, Liu W, Cottam HB, Leoni LM, Carson DA, Zhang XK. The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2525-30.

Lin B, Kolluri SK, Lin F, Liu W, Han YH, Cao X, Dawson MI, Reed JC, Zhang XK. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell. 2004 Feb 20;116(4):527-40.

Kolluri SK, Bruey-Sedano N, Cao X, Lin B, Lin F, Han YH, Dawson MI, Zhang XK. Mitogenic effect of orphan receptor TR3 and its regulation by MEKK1 in lung cancer cells. Mol Cell Biol. 2003 Dec;23(23):8651-67.

Li H, Kolluri SK, Gu J, Dawson MI, Cao X, Hobbs PD, Lin B, Chen G, Lu J, Lin F, Xie Z, Fontana JA, Reed JC, Zhang X. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science. 2000 Aug 18;289(5482):1159-64.

Kolluri, SK., Balduf C., Hofmann M. and Goettlicher, M. Novel target genes of the Ah (Dioxin) receptor: transcriptional induction of N-myristoyltransferase 2. Cancer Research 61: 8534-9, 2001.

Kolluri SK, Weiss C, Koff A, Gottlicher M. p27(Kip1) induction and inhibition of proliferation by the intracellular Ah receptor in developing thymus and hepatoma cells. Genes Dev. 1999 Jul 1;13(13):1742-53.

 

At OSU

Headquarters: 
OSU Main Campus
I accept graduate students for the Environmental and Molecular Toxicology Department
Courses Taught: 

Tox 512: Target Organ Toxicology: Molecular Mechanisms

Tox 699: Molecular Therapeutics - Discovery and Development

Professional Accomplishments

Professional Affiliations: 
  • Cancer Prevention and Intervention Program, Linus Pauling Institute, Oregon State University
  • Department of Biomedical Sciences, Oregon State University
  • Department of Biochemistry & Biophysics, Oregon State University

 

Employment: 

Professor of Cancer Research

 

Faculty member, Cancer Prevention and Intervention Program, Linus Pauling Institute, Oregon State University 2014 - present

Associate Professor of Cancer Research

2012 - 2018

Assistant Professor of Cancer Biology
Oregon State University, Corvallis, OR

2006-2012

Research Assistant Professor
Burnham Institute for Medical Research, La Jolla, CA

2005-2006

Staff Scientist
Burnham Institute for Medical Research, La Jolla, CA

2002-2004

Post Doctoral Associate
with Dr. Xiao-Kun Zhang, Burnham Institute for Medical Research, La Jolla, CA

1999-2002

Officer (Operations): Indian Vaccines Corporation, New Delhi, India                                        1992-1995

Officer (Operations-Technology Transfer): Pasteur Merieux Connaught, Lyon, France        1991-1992

 

Education: 

Post Doctoral Research
Mentor: Professor Xiao-Kun Zhang, Burnham Institute for Medical Research, La Jolla, CA

Ph.D. - Magna Cum Laude
The Institute of Genetics, University of Karlsruhe, Germany
(Director: Professor Peter Herrlich)
Thesis Mentor: Professor Martin Göttlicher

Master of Technology (Bio-Technolgy)
Jadavpur University, Calcutta, India

Bachelor of Pharmacy (Hons.)
Biria Institute of Technology and Science, Pilani, India

 

My Awards

Honors and Awards: 
  • Awarded University gold medal for being a topper at Jadavpur University, Calcutta, India (1990).

  • Awarded Ph.D. degree with magna cum laude (1999).

  • American Cancer Society Research Scholar Award

  • Short-listed for the prestigious Era of Hope Scholar award from the Breast Cancer Research Program, Department of Defense (2004).

  • New Investigator Award from California Tobacco Related Disease Research Program (2003-2006).

  • Post-doctoral fellowship from Department of Defense Breast Cancer Research Program (2000-2003).

  • Fellowship for doctoral research from Research Center Karlsruhe, Germany (1995-98).

 

PATENTS

  • Siva Kumar Kolluri, Nancy I. Kerkvliet et al., Aryl Hydrocarbon Receptor Activators. 2020.

  • Kopparapu, P; Pearce, M and Kolluri, S.K. Bcl-2 functional converters. 2019.

  • Nancy I. Kerkvliet and Siva Kumar Kolluri. Compounds and Methods to suppress autoimmune response. Patent No. # US10308649B2, 2019;

  • Nancy I. Kerkvliet and Siva Kumar Kolluri. Compounds and Methods to suppress autoimmune response. European patent application: EP15855322.2

  • Satterthwait, A., Zhang, X.K, Zhu, X., and Kolluri, S.K. Methods of regulating apoptosis. Patent No. # US20100292145A1, 2010.

  • Kolluri, S.K., Zhu, X., Zhang, X., and Satterthwait, A. Targeting Bcl-2 family proteins with cell-permeable peptides. US Patent No. # 20070054863, 2008.

  • Reed, J.C., Zhang, X., Gao, B., Lin, B. and Kolluri, S.K. Bcl-2 Converters for Cancer. US Patent No. # 6,994,979, 2006.

  • Göttlicher, M., Kolluri, S.K., and Weiss, C. Method for producing agents for treating tumor diseases and for immunosuppression Patent No. # US 6,482,610 B1, 2002.

  • Göttlicher, M., Kolluri, S.K., and Weiss, C. Method for evaluation of toxicity of environmental pollutants. Patent No. # Europe 198 11 326, 1999.

 

My Publications

My Media

A drug that lots of post-menopausal women take to prevent and treat osteoporosis keeps making news and the latest comes from Oregon State University researchers.